|
| |
 |
 |
 |
 |
| |
|
|
| |
 |
| |
| Members in the News - 2006 |
| |
 |
| |
Neal Gordon, CEO of Epitome Biosystems in Waltham, announced that his company has received a second SBIR grant of $500k to study cellular activity and drug responses.
Epitome's EpiTag product is used to develop antibody pairs for the measurement of proteins and to aid in drug discovery. The story is reported in Mass High Tech, 12/14/06.
Congratulations to Neal and his team on the progress they are making in the development of Epitome's protein-testing products.
Neal is a member of CEO Roundtable. |
| |
|
| |
 |
| |
The front page of the Sunday Eagle-Tribune (Dec. 10) featured a story about and photos of Dick Sumberg and his wife, Lolli, working on a Habitat for Humanity house that they decided to build in Lawrence to commemorate their 60th birthdays. Dick has been building this house since last spring. He recruited friends, customers and fellow CEO Roundtable members to help with the labor and contribute materials and construction services.
Dick has been giving his Roundtable group monthly updates on the progress of the construction. He is especially pleased that he was able to do more than write a check this time.
We are proud of what Dick has accomplished and the example he has set for giving back by using his back.
Dick Sumberg is a 10 year member of CEO Roundtable. |
| |
|
| |
 ; |
| |
Charles Sherwood, CEO of Anika Therapeutics, announced that the company has received an "approvable letter" from the FDA which could mean that the FDA will soon approve Anika's cosmetic tissue-augmentation product. Investors responded by bidding up share prices over 20%. (NASDAQ: ANIK). For more details, please see Boston Globe, November 19, 2006, page F5.
This HA based product is for use as an injectable soft-tissue filler for wrinkles, scars, and lip augmentation.
Chuck is a member of one of the CEO Roundtables for biotech/pharma companies. |
| |
|
| |
 |
| |
Peter Savas, chairman & CEO, Boston Life Sciences, was interviewed by R.D. Sahl on NECN TV's Business Day progam. He reviewed the status of clinical trials for several of BLS's leading products, including ALTROPANE, a molecular-imaging agent that is in Phase III trials. It is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or essential tremors. The interview can be seen at www.necn.com.
Boston Life Sciences is a public company listed on NASDAQ. See www.bostonlifesciences.com. |
| |
|
| |
 Sarah Fuller's picture is in Mass High Tech, (Sept. 15-21, p. 19). She is shown receiving the CEO Roundtable Leadership Award for 2006.
Sarah received this award for the example she set in finding the best buyer for a majority share of her company, Decision Resources, and the subsequent expansion of the company to the benefit of her employees and customers. Sarah still owns a substantial share of the company and continues to provide the daily leadership and the long term vision for the company. She continues to build her legacy. |
| |
We are very proud to have Sarah Fuller as a longtime member of CEO Roundtable.
PS: We shared the page in MHT with photos of Doug Flutie -- good company! |
| |
|
| |
 |
| |
Peter Savas, chairman & CEO, Boston Life Sciences, was interviewed by R.D. Sahl on NECN TV's Business Day progam. He reviewed the status of clinical trials for several of BLS's leading products, including ALTROPANE, a molecular-imaging agent that is in Phase III trials. It is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or essential tremors. The interview can be seen at www.necn.com.
Boston Life Sciences is a public company listed on NASDAQ. See www.bostonlifesciences.com. |
| |
|
| |
 |
| |
Mike Dempsey, founder of Radianse, is expanding his company's product and service offering for hospitals through a joint marketing agreement with Patient Care Technology Systems of California. The story is reported in Mass High Tech, Aug 29.
Radianse will integrate PCTS's hospital workflow software into its RFID-based indoor-positioning and tracking systems, which it is installing at hospitals across the country. The combination of the products will provide fully integrated work flow systems to hospitals, thereby improving patient care and reducing costs.
Mike is a long-time member of the high tech peer group within CEO Roundtable. |
| |
|
| |
 |
| |
Dennis Goldberg, CEO of Transport Pharmaceuticals, is profiled in the August 25 issue of Mass High Tech (page 18).
The article by Patricia Resende describes Dennis's drive to build companies that develop and deliver lifesaving drugs and technologies. He chose Pfizer over academia because he wanted to be more directly involved in delivering new drugs. The large corporate environment didn't meet his needs and he soon moved into start-up biotech, working on the front lines of developing therapies for AIDS and other diseases.
Dennis was named CEO of Transport Pharmaceuticals which recently announced the continuation of a significant relationship with GlaxoSmithKline to test and market a new treatment for herpes. See www.transportpharma.com.
Great photo, Dennis! |
| |
|
| |
 |
| |
Walter Ogier, CEO of Arbios, Inc., is pictured in a Boston Business Journal story (8/4/06) about the company's efforts to develop an "artificial liver." Arbios has developed HepatAssist, a external device that cleans toxins from the blood in patients with liver disease. The device is intended to help patients until they can receive a liver transplant.
Walter took over as CEO of the OTC listed company last fall and moved it to Boston from California. This is a restart for the technology, which has been improved and recently received FDA approval for new clinical trials. Seewww.arbios.com. |
| |
|
| |
|
| |
Walter Ogier, CEO of Arbios, Inc., is pictured in a Boston Business Journal story (8/4/06) about the company's efforts to develop an "artificial liver." Arbios has developed HepatAssist, a external device that cleans toxins from the blood in patients with liver disease. The device is intended to help patients until they can receive a liver transplant.
Walter took over as CEO of the OTC listed company last fall and moved it to Boston from California. This is a restart for the technology, which has been improved and recently received FDA approval for new clinical trials. See www.arbios.com.
Walter is a member of CEO Roundtable.
Dennis Goldberg, CEO, Transport Pharmaceuticals, announced the company has closed on additional funding of $12.6m. Transport Pharmaceuticals will use the funds to continue research in treatment of herpes labialis (cold sores). The company has developed a drug delivery platform based on a technology employing a low-voltage electrical charge to deliver medications through the skin. Patients can self-administer doses of medication from pre-filled cartridges.
The round of financing was led by current investor The Carlyle Group of Washington, D. C. Transport has raised a total of $35.6m. The story is reported in MHT, August 1, 2006..
Dennis is a member of CEO Roundtable. Congratulations to Dennis and his team on this significant milestone. |
| |
|
| |
| Loren Carlson honors Sarah W. Fuller with 2006 "CEO Roundtable Leadership Award" |
| |
 CEO Roundtable honored Sarah W. Fuller, President and COO of Decision Resources, Inc., on July 12 with the second annual "CEO Roundtable Leadership Award."
"The Leadership Award is given in recognition of Sarah's exemplifying the power of peer groups to help members increase the value of their companies and enrich the quality of their lives," Loren G. Carlson, Chairman of CEO Roundtable, said.
Sarah Fuller is the president, chief operating officer, and board director of Decision Resources Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues. The Waltham, Mass.-based company is best known for its therapeutically focused analyses of global pharmaceutical and biotechnology markets and for its research on the U.S. managed care industry through its HealthLeaders-InterStudy subsidiary. More than 1,000 clients use Decision Resources' services for their strategic planning, market development, technology management, competitive intelligence, and investment requirements.
Sarah is a very long-time member of CEO Roundtable. In his remarks Loren Carlson stressed that Sarah is a leading example of enlightened business leadership. She has proved that forgoing short term personal financial gain for other business values can increase the long term returns for all. Sarah had several options when selling a majority share in the company but she chose the one that she believed gave the company and the employees the greatest chance at staying focused on the mission of providing the best information to its customers.
"Sarah showed us that you can have it all -- the resources for growth and the freedom to make the best long-term decisions for everyone," said Loren.
Several members of Sarah's Roundtable peer group added their observations of why she deserves the CEO Roundtable Leadership Award, noting the low employee turnover, the strategic consistency and the life balance at Decision Resources. Indeed the story of Sarah Fuller and Decision Resources is one that could easily have been included in Bo Burlingham's recent book, Small Giants: Companies That Choose to Be Great Instead of Big.
Mrs. Fuller's current responsibilities include driving double-digit growth in revenues and profits for Decision Resources, Inc., as well as building new partnerships such as their recent joint venture with PharMetrics and the acquisition of Millennium Research Group.
Previously, Mrs. Fuller was a vice president at Arthur D. Little, Inc., a consulting firm with specialties in many sectors including chemical, pharmaceutical, and high-tech. During her 29 years at Decision Resources, she has served 20 years as its president. In 1990, Sam Fleming and Mrs. Fuller led a buyout of Arthur D. Little Decision Resources from Arthur D. Little, Inc.
In 2003, Castanea Partners and Boston Ventures Limited Partnership VI became the majority shareholders in Decision Resources, bringing the added capital and the financial and operating experience necessary for the company to accelerate its strategy and growth. Mrs. Fuller continues to serve as its president, chief operating officer, and board director.
Mrs. Fuller is on the board of Cultural Survival, a Harvard University-affiliated non-profit organization that promotes the vision, rights and voice of indigenous people, and the Huntsman's Program at the University of Pennsylvania. She has led numerous worldwide consulting studies focusing on management and strategy issues within the pharmaceutical industry. Mrs. Fuller holds a B.A. from the University of Pennsylvania and an A.M. from Harvard University.
Robert M. Glorioso, a long-time CEO Roundtable member, was the first recipient of the CEO Roundtable Leadership Award, given in recognition of his outstanding and illustrious credentials that include major contributions to computer hardware and software technology development, and to honor his career as a "serial entrepreneur." |
| |
|
| |
|
| |
Mike Dempsey, Radianse, recently announced the completion of a $6m round of financing. The additional funds will be used to fuel the rapid growth of the company and new product development. See Boston Business Journal, July 13, 2006.
National Healthcare Services led this round, which included returning investors Partners Healthcare, HLM Venture Partners, Partech International, Ascension Health Ventures, and Kaiser Permanente.
Radianse is installing its RFID based information systems in hospitals around the country, including Mass General and Brigham & Women's in Boston.
Mike is a longtime member of CEO Roundtable.
Congratulations to Mike and his team for their continued success. |
| |
|
| |
|
| |
Charles (Chuck) Sherwood, CEO, Anika Therapeutics, announced a worldwide development and commercialization agreement with Galderma Pharmaceutical, a Swiss company, for further development and marketing of Anika's tissue augmentation therapy and other cosmetic products. The Swiss company is a joint venture between Nestle and L'Oreal. The news was reported in Mass High Tech Flash Report, July 5, 2006.
This marks another step forward in Anika's diversification of its hyalaronic acid-based product line. Anika Therapeutics is a public company with revenues of $29.8m in 2005. See www.AnikaTherapeutics.com.
Congratulations to Chuck and his team. Chuck is a long time member of CEO Roundtable. |
| |
|
| |
 |
| |
Mercia Tapping's company, AllergyBuyersClub, was selected by Boston Business Journal as one of the Best Places to Work in the small business category.
AllergyBuyersClub.com sells healthy home products on the web and through a print catalog, e.g., air purifiers, dehumidifiers, Hepa vacuums and hypoallergenic bedding to meet the needs of allergy, asthma, and sinus sufferers.
See www.AllergyBuyersClub.com.
Mercia joined CEO Roundtable when she started her company in her home. She has been recognized with several regional and national awards for her success as an entrepreneur. Two members of the Roundtable serve on Mercia's board of advisors.
Congratulations to Mercia and her team for creating a "Best Place to Work." |
| |
|
| |
 |
| |
Michael Webb, CEO of Ascent Therapeutics, has been elected the next Chair of the Mass Biotech Council. MBC with over 500 members is the leading association for the biotechnology and pharmaceutical industry in New England. As the Chairman of MBC, Mike will oversee MBC's efforts to continue the development of the life sciences as the leading economic resource for our area and to support the success of the members. See www.MassBio.org.
Mike is a long time member of CEO Roundtable. He was the CEO of Epix Pharmaceuticals for 11 years and recently founded Ascent Therapeutics.
We congratulate Mike for taking on this additional responsibility. We need people of Mike's character and talent as our leaders. |
| |
|
| |
 |
| |
Agencourt Personal Genomics of Beverly, MA announced that it has agreed to sell the company for $120m to Applied Biosystems in California. The purchase was reported by Mass High Tech.
Congratulations to Brian McKernan, CEO of Agencourt, and his team on the success of the company. |
| |
|
| |
Mike Webb has announced his plans to start Ascent Therapeutics. Mike is the former CEO of Epix Pharmaceuticals, a public company, which recently merged with Predix Pharmaceuticals.
The Boston Business Journal (May 20, pg 7) reports that Ascent Therapeuptics will focus on oncology and inflamation treatments utilizing new discoveries at Tufts-New England Medical Center. Mike is planning to develop partnerships with large pharmaceutical companies in India.
Mike is a long time member of CEO Roundtable.. |
| |
|
| |
 |
| |
Kedar Gupta's company, GT Solar, a divison of GT Equipment in Merrimack, NH, has completed phase one of a turnkey solar manufacutring line for LDK Solar in China. Mass High Tech reports that LDK Solar's ultimate plan is to expand this to a 1-gigawat manufacturing line.
Congratulations to Kedar and his team for achieving this milestone in this long term contract.. |
| |
|
| |
 |
AScott Gillis, the CEO of Nucryst Pharmaceuticals, is featured in a Boston Business Journal story (April 21, pg 13) about his company's plans to expand after a successful IPO which raised over $42m and spun it out of its parent company.
Nucryst has a very healthy revenue stream from its antimicrobial coating products used to treat burn victums and other wounds. The company will leverage its core nanotechnology to expand its product line to other therapeutic areas including atopic dermatitis and gastrointestinal disorders. Nucryst's core technology is its ability to dismantal silver atom by atom and reassemble it into differnt forms of silver with enhanced microbial properties. See www.nucryst.com.
Scott has been leading Nucryst in the succesful commercialization of it products with its distribution partner, Smith & Nephew, and positioning the company to crossover from medical devices to pharmaceuticals.
Scott is long time member of CEO Roundtable. |
| |
|
| |
 |
| |
Andrew Barnett's new healthy dessert, Alpine Ice, is highlighted in the food section of the Boston Globe, March 29, C2. The report says,
"Alpine Ice, infused with herbs, fruit, tea, and all natural flavors provides an option for those who avoid sweets, dairy, egg, soy, wheat, or nuts".
Andy is co-founder of Mountain Herbal Foods of Marblehead. The company created this very tasty dessert for those with allergies or who prefer to be vegan. Alpine Ice is currently available only in Massachusetts and can be bought at Whole Foods Markets and other specialty food stores. For a current listing of stores selling Alpine Ice go to www.mtnherbal.com.
Andy is a long time member of CEO Roundtable -- and we have been his "first tasters" from the start. We served Alpine Ice at the recent CEO Roundtable Retreat at Babson College. |
| |
|
| |
 |
| |
Martin Reid, CEO of Ibis Technology in Danvers, MA, announced that Sumitomo Mitsubishi Silicon Corp, the world's second largest silicon wafer manufacturer, has given final customer acceptance for the Ibis i2000 oxygen implanter AND has confirmed its order for a second $7m machine. The story is reported in Mass High Tech (MHT) , March 13.
Ibis Technology manufactures the complex machines that are used to produce large silicon wafers that have oxygen atoms implanted to serve a insulators, permitting silicon chips to run at higher speeds and at lower temperatures. SUMCO will be providing the semiconductor industry with chips that will increase the speed and versatility of a variety of computers.
Congratulations to Martin (Woody) Reid and his team on the accomplishment of this milestone -- it has taken years of perseverance. |
| |
|
| |
|
| |
Walter Ogier, CEO, Arbios Systems, has completed a private placement of $1.35m for continued development of the company's proprietary liver assist devices and new technologies to be used in the diagnosis and treatment of liver failure.
LibertyView Capital Management led the investment.
Arbios Systems trades on Over the Counter Bulletin Board. See www.arbios.com. The news is reported in Mass High Tech today.
Walter is a member of CEO Roundtable. |
| |
|
| |
|
| |
Charles Sherwood, CEO, Anika Therapeutics, announced that Anika has received approval from the European Union to market Redefyne in Europe. Redefyne is a cosmetic augmentation product based on Anika's propriety technology for chemically modified hyaluronic acid (HA) which can be injected into soft tissue for wrinkles, scar remediation and lip augmentation. Anika has applied to the FDA for pre-market approval for this same product in the US. The story is reported in Mass High Tech, Feb 17.
Congratulations to Chuck and his team for achieving another milestone in the commercialization of their research, development and manufacturing efforts.
Anika is listed on NASDAQ. See www.anikatherapeutics.com for information on other Anika products.
Chuck Sherwood is a long time member of CEO Roundtable. |
| |
|
| |
 |
| |
Sarah Fuller, co-founder and President, Decision Resources Inc. in Waltham, announced the acquisition of Millennium Research Group in Toronto, Canada.
Decision Research Inc is a global leader in market research for the pharmaceutical and biotechnology industries. DRI is engaged in an aggressive expansion to build a portfolio of services that provide insight to customers who are increasingly focused on the junction between drugs and devices. The story is reported in Mass High Tech, Feb 3.
Congratulations to Sarah and her team.
Sarah is a long time member of CEO Roundtable. |
| |
|
| |
| |
| |
Scott Gillis, NUCRYST, goes public, gets $46m
Scott Gillis, CEO, NUCRYST Pharmaceuticals in Wakefield ended the year with a successful IPO on Dec 22, 2005. This was the last IPO in the whole country in 2005 and one of the few biotech IPOs in Boston the whole year. NUCRYST raised over $46m. Its stock is traded on NASDAQ (NCST) and Toronto (NCS).
NUCRYST Pharmaceuticals was spun out of Westaim, a Canadian company. The company is especially well known for its burn and wound dressings that utilize nanotechnology to increase the healing properties of nanocrystalline silver. The company has other products in the development pipeline.
Scott is a member of CEO Roundtable -- and we couldn't be happier for him and his team. See www.nucryst.com. |
| |
|
| |
 |
| |
Sig Tullmann, CEO of Safe Hydrogen, announced that the company has been awarded $308k to complete its work for the Department of Energy to confirm the functionality, efficiency and cost of Safe Hydrogen's proprietary compound to store, transport and generate hydrogen. The story is reported in Mass High Tech today.
Safe Hydrogen has developed a safe, pump able hydrogen rich fuel that releases hydrogen as needed. The pump able hydride slurry is not flammable, is safe to handle, and is easy to store in the current pumps and tanks used for diesel fuel, gasoline or water. These characteristics should help to overcome one of the obstacles to the widespread use of hydrogen fuel in motor vehicles, the need for a national infrastructure to store and distribute the fuel.
Sig is long time member of CEO Roundtable. |
| |
|
| |
 |
| |
Kedar Gupta, Founder and CEO of GT Equipment Technologies in Merrimack, NH announced the sale of the majority interest in the company to GFI Energy Ventures of Los Angeles. The company will continue to operate in Merrimack and Kedar and his team will continue to run the business.
GT Equipment Technologies is a world leader in the design, construction, and deployment of photovoltaic factories. These turnkey assembly lines have been sold around the globe with most of the recent sales in China, Taiwan and the other Asian countries. GT has a very large backlog of contracts. GT will use the funds from the investors to continue its expansion.
This has been a remarkable story of the strength of the entrepreneurial spirit. When Kedar joined CEO Roundtable he was facing very difficult business challenges and the vultures were circling. We are all very proud of Kedar and what he and his team accomplished. It is a tale worth the telling.
GFI Energy Ventures is a private equity firm focused on energy infrastructure companies. |
| |
|
| |
 |
| |
David Dove's company, Aeris Therpeutics, has been granted "Fast-Track" status by the FDA for its non-surgical treatment of advanced emphysema. The treatment is called bronchoscopic lung volume reduction (BLVR).
Aeris has completed Phase 1 trials and the Fast-Track designation may accelerate the FDA approval process.
See www.aerist.com
The story is reported in Mass High Tech, Dec 12, page 8.
The FDA "Fast-Track" designation is reserved for drug and biological development programs that are intended to to treat serious or life threatening conditions and that demonstrate the potential to address crucial medical needs.
David Dove is a member of one of the CEO Roundtables for biotech companies. |
| |
|
| |
|
|
|
